AgeX Therapeutics, Inc. announced that ImStem Biotechnology, Inc., a biopharmaceutical company developing human ESC-derived mesenchymal stem cells, has dosed the first US multiple sclerosis patient with ImStem’s lead investigational drug candidate IMS001.
[AgeX Therapeutics, Inc.]
7992332
{7992332:CCCCCCCC}
apa
50
1
169549
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
